Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting

Galiën, Hilde T van der; Hoogendoorn, Mels; Kibbelaar, Robby E.; Meerten, Tom van; Rijn, R.S. van

doi:10.1093/annonc/mdy482

Cited by 6 publications

(5 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2019, published data from the Netherlands by Van der Gali€ en et al 19 , supported Maurer's findings, where patients who achieved PFS24 (319 patients from a total of 585) had an OS that was similar to Maurer's cohort. The follow-up time was >10 years and PFS24 was calculated from the end of treatment.…”

Section: Discussionmentioning

confidence: 70%

Age is the most important predictor of survival in diffuse large B‐cell lymphoma patients achieving event‐free survival at 24 months: a Swedish population‐based study

et al. 2021

View full text Add to dashboard Cite

Summary Routine follow‐up for diffuse large B‐cell lymphoma have been shortened to 2 years when event‐free survival at 24 months (EFS24) emerged as a new milestone. In the present study, we aimed to determine whether the achievement of this milestone affected overall survival (OS). We compared OS to that of an age‐ and sex‐matched population, analysed other factors governing OS, and reviewed the causes of death. Data were collected from the Swedish Cancer Registry and from individual patient’s records. We included 1169 adult patients from five counties between the years 2001 and 2014. The median (range) age was 64·6 (18–91) years, 56·6% were men and the median follow‐up was 82·3 months. For early stages, the achievement of EFS12 did not improve OS. More than two‐thirds of the patients (n = 837, 71·6%) achieved EFS24, of which 190 (22·7%) died during follow‐up. Lymphoma (20%), cardiovascular disease (22·4%) and malignancies (16%) contributed to causes of death. Patients aged <60 years had an OS that matched the standard population. In multivariate analysis, only age >60 years significantly affected OS after EFS24 compared with the standard population. We concluded that follow‐up beyond EFS24 should be considered for patients aged >60 years.

show abstract

Section: Discussionmentioning

confidence: 70%

Age is the most important predictor of survival in diffuse large B‐cell lymphoma patients achieving event‐free survival at 24 months: a Swedish population‐based study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The three proposed indexes had a similar 5 years OS for the high‐risk group (46%‐52%), but the proportion of patients classified as poor‐risk were 37%, 20%, and 32%, respectively—lower than the 44% identified with R‐IPI. These proportions seem to us to be closer to “real life” clinical practice experience, where with current first line therapies, various salvage regimens and the best supportive therapies, about 25%‐35% of patients were seen to have truly bad outcomes(5 years OS 48%) 26‐29 . Thus in the light of these observations, we believe that the R‐IPI tends to overestimate the percentage of high‐risk patients, while models 1, 2, and 3 are more likely to recognize patients who are truly at higher risk.…”

Section: Discussionmentioning

confidence: 71%

Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma

Marcheselli

Bari

Tadmor

et al. 2020

Hematological Oncology

View full text Add to dashboard Cite

The main purpose of this study was to assess whether it is possible to improve the prognostic impact of international prognostic index (IPI) score by combining it with peripheral blood counts. Thus, we evaluated the prognostic power of lymphocyte, neutrophil, and monocyte counts in 520 patients with diffuse large B cell lymphoma treated with R-CHOP, confirming that these parameters have a strong impact on overall survival (OS). Using revised IPI (R-IPI), 44% of patients were categorized as poor-risk and showed an OS at 5 years of 46%. As OS at 5 years of the 520 patients is 67%, it is clearly evident that R-IPI tends to overestimate the proportion of patients with poor prognosis. Accordingly, in an attempt to improve the discriminating power of R-IPI, we evaluated and compared three different scores by combining the neutrophil lymphocyte ratio (NLR) and absolute monocyte count (AMC) with the following values: (a) IPI score 3-5, (b) age > 60 years and performance status, (c) age ≥ 65 years and LDH > ULN. The three indexes studied, had a similar 5 years OS for the high-risk group (46%-52%), but the proportion of patients classified as poor-risk were 37%, Raffaella Marcheselli and Alessia Bari contributed equally to this study.

show abstract

“…Hence, daily clinical practice matches clinical trial data (Supplementary Table 1 ) [ 1 , 8 ]—or vice versa—in this high-risk population. The results of the re-analysis of R-Benda confirm the 2y-PFS as a surrogate endpoint [ 1 , 8 , 9 ].…”

mentioning

confidence: 75%

Evidence of bendamustine plus rituximab for old and frail patients with aggressive B-cell lymphoma

Schalk

Jentsch-Ullrich²

2023

Ann Hematol

View full text Add to dashboard Cite

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting

Cited by 6 publications

References 3 publications

Age is the most important predictor of survival in diffuse large B‐cell lymphoma patients achieving event‐free survival at 24 months: a Swedish population‐based study

Age is the most important predictor of survival in diffuse large B‐cell lymphoma patients achieving event‐free survival at 24 months: a Swedish population‐based study

Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma

Evidence of bendamustine plus rituximab for old and frail patients with aggressive B-cell lymphoma

Contact Info

Product

Resources

About